Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.36 |
| ▸ | FLT1 | P17948 | 6/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | KIF5B | P33176 | 1/20 | 0.35 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.34 |
| ▸ | FLT4 | P35916 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.32 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116322 | 0.85 | SRC (0.36) | KDREGFRRETGPR119RAF1 | |
| SCHEMBL10105778 | 0.82 | GPR119 (0.41) | KDRFLT1FGFR1LRRK2EGFR | |
| SCHEMBL10116318 | 0.77 | GPR119 (0.53) | GPR119 | |
| SCHEMBL10105801 | 0.77 | MKNK2 (0.39) | KDRFLT1FGFR1LRRK2EGFR | |
| SCHEMBL10116293 | 0.74 | TRPA1 (0.39) | LRRK2GPR119 | |
| SCHEMBL10116316 | 0.74 | GPR119 (0.43) | KDRFLT1FGFR1LRRK2EGFR | |
| SCHEMBL10116320 | 0.73 | GPR119 (0.50) | GPR119 | |
| SCHEMBL10116431 | 0.71 | KDR (0.37) | KDRFLT1FGFR1LRRK2EGFR | |
| SCHEMBL12170624 | 0.70 | KDR (0.33) | KDRFLT1FGFR1LRRK2EGFR | |
| SCHEMBL10116310 | 0.70 | GPR119 (0.34) | EGFRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | KDR 527/4885FLT1 1152/4885FGFR1 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.